MedPath

Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Insulin glargine (HOE901)
Drug: Insulin glargine new formulation (HOE901)
Registration Number
NCT01689142
Lead Sponsor
Sanofi
Brief Summary

Primary Objective:

To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at month 6 \[week 26\]) in japanese patients with type 2 diabetes mellitus.

Secondary Objectives:

To compare a new formulation of insulin glargine and Lantus in terms of change in fasting plasma glucose (FPG), preinjection plasma glucose, 8-point self-measured plasma glucose (SMPG) profile.

To compare a new formulation of insulin glargine and Lantus in terms of occurrence of hypoglycemia

Detailed Description

The duration of study will consist of:

* Up to 2-week screening period;

* 6-month open-label comparative efficacy and safety treatment period;

* 6-month open-label comparative safety extension period;

* 4-week post-treatment safety follow-up period

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
240
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Lantus (insulin glargine)Insulin glargine (HOE901)once daily in the evening on-top of OADs
New formulation of insulin glargineInsulin glargine new formulation (HOE901)once daily in the evening on-top of oral antihyperglycemic drug (OADs)
Primary Outcome Measures
NameTimeMethod
Change from baseline in HbA1cbaseline, 6 months
Secondary Outcome Measures
NameTimeMethod
Change from baseline in FPGbaseline, 6 months
Percentage of HbA1c responders (HbA1c < 7%; < 6.5%)up to 6 months
Change from baseline in pre-basal insulin injection SMPGbaseline, 6 months
Change from baseline in 8-point SMPG profilesbaseline, 6 months
Change from baseline in 24-hour mean plasma glucose of SMPG profiles (mean of 8-point values)baseline, 6 months
Change from baseline in variability of plasma glucose profilebaseline, 6 months
Change from baseline in daily basal insulin dosebaseline, 6 months
Number of patients with various types of hypoglycemia eventsup to 6 months

Trial Locations

Locations (31)

Investigational Site Number 392226

🇯🇵

Amagasaki-Shi, Japan

Investigational Site Number 392223

🇯🇵

Izumisano-Shi, Japan

Investigational Site Number 392209

🇯🇵

Chuo-Ku, Japan

Investigational Site Number 392208

🇯🇵

Chuoh-Ku, Japan

Investigational Site Number 392218

🇯🇵

Chigasaki-Shi, Japan

Investigational Site Number 392217

🇯🇵

Ebina-Shi, Japan

Investigational Site Number 392212

🇯🇵

Chiyoda-Ku, Japan

Investigational Site Number 392204

🇯🇵

Kawaguchi-Shi, Japan

Investigational Site Number 392206

🇯🇵

Kisarazu-Shi, Japan

Investigational Site Number 392231

🇯🇵

Okawa-Shi, Japan

Investigational Site Number 392211

🇯🇵

Mitaka-Shi, Japan

Investigational Site Number 392224

🇯🇵

Osaka-Shi, Japan

Investigational Site Number 392207

🇯🇵

Shinjuku-Ku, Japan

Investigational Site Number 392221

🇯🇵

Takatsuki-Shi, Japan

Investigational Site Number 392210

🇯🇵

Chuo-Ku, Japan

Investigational Site Number 392216

🇯🇵

Fujisawa-Shi, Japan

Investigational Site Number 392222

🇯🇵

Higashiosaka-Shi, Japan

Investigational Site Number 392215

🇯🇵

Kamakura-Shi, Japan

Investigational Site Number 392225

🇯🇵

Kashiwara-Shi, Japan

Investigational Site Number 392205

🇯🇵

Kawagoe-Shi, Japan

Investigational Site Number 392201

🇯🇵

Koriyama-Shi, Japan

Investigational Site Number 392228

🇯🇵

Kurashiki-Shi, Japan

Investigational Site Number 392229

🇯🇵

Matsuyama-Shi, Japan

Investigational Site Number 392230

🇯🇵

Matsuyama-Shi, Japan

Investigational Site Number 392203

🇯🇵

Ogawa-Machi, Hikigun, Japan

Investigational Site Number 392220

🇯🇵

Nagoya-Shi, Japan

Investigational Site Number 392202

🇯🇵

Ushiku-Shi, Japan

Investigational Site Number 392227

🇯🇵

Nishinomiya-Shi, Japan

Investigational Site Number 392219

🇯🇵

Shizuoka-Shi, Japan

Investigational Site Number 392214

🇯🇵

Yokohama-Shi, Japan

Investigational Site Number 392213

🇯🇵

Yokohama-Shi, Japan

© Copyright 2025. All Rights Reserved by MedPath